Vyndaqel Market, By Indication (Wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, wild-type), Hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM, variant), and Transthyretin-mediated amyloidosis polyneuropathy (ATTR-PN/FAP) ), By Strength ( 20 mg and 61 mg), By Payer (Public, Private, and Self-pay/Out-of-pocket), By Distribution Channel ( Hospital pharmacies, Specialty/Online pharmacies, and Retail pharmacies), By End User ( Hospitals, Cardiac Amyloidosis Centers, Ambulatory Surgical Centers, and Homecare Settings), By Age group ( Adults (≥18 yrs) and Elderly (≥65 yrs)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Select a License Type that Suits your Business Needs
US$ 2,000
Two thousand dollars
Single User License
( Full Report )
US$ 4,500
US$ 3,000
Three thousand dollars
Frequently purchased
Multi User License
( Full Report )
US$ 7,000
US$ 5,000
Five thousand dollars
Corporate User License
( Full Report )
US$ 10,000
US$ 6000
Six thousand dollars
Client Testimonials
Client Testimonials
Our Clients
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.

860519526
9001:2015
27001:2022